ALEXANDER J GALLAN

Allopathic & Osteopathic Physicians|Pathology|Anatomic Pathology MILWAUKEE, WI NPI 1780023101

General Payments — all program years on this page

$14,958.68

  • Category: General Payments
  • Program years: PY2019–2024
  • Record count: 24
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $11,850.15 across 16 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2019 $227.822
2021 $194.943
2022 $600.001
2023 $2,085.772
2024 $11,850.1516

Records — PY2024 (16)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086919925 Novartis Pharmaceuticals Corporation $57.76 08/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919927 Novartis Pharmaceuticals Corporation $54.04 08/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919929 Novartis Pharmaceuticals Corporation $12.99 09/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919933 Novartis Pharmaceuticals Corporation $2,300.00 09/04/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086919945 Novartis Pharmaceuticals Corporation $127.10 10/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919949 Novartis Pharmaceuticals Corporation $34.56 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919955 Novartis Pharmaceuticals Corporation $34.00 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919957 Novartis Pharmaceuticals Corporation $928.55 09/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086919959 Novartis Pharmaceuticals Corporation $333.89 09/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086919961 Novartis Pharmaceuticals Corporation $4,300.00 09/24/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Undisputed 01/23/2026 View at CMS
1086919963 Novartis Pharmaceuticals Corporation $23.67 09/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919965 Novartis Pharmaceuticals Corporation $131.35 09/24/2024 Travel and Lodging Undisputed 01/23/2026 View at CMS
1086919969 Novartis Pharmaceuticals Corporation $60.81 08/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919971 Novartis Pharmaceuticals Corporation $62.07 08/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086919973 Novartis Pharmaceuticals Corporation $126.86 10/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118836709 Otsuka Pharmaceutical Development & Commercialization, Inc. $3,262.50 11/05/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.